Publications by authors named "L Tomassini"
Background: Pazopanib is part of the therapeutic armamentarium for the treatment of patients with advanced non-adipocytic soft tissue sarcomas (STS) who have received prior chemotherapy, but its optimal use in STS histologies is still left to be further defined.
Design And Methods: Data on STS patients treated with pazopanib in Italy have been prospectively collected from July 2013 to December 2019 through a drug monitoring registry managed by the Italian Medicines Agency (AIFA). This nationwide observational cohort study included patients with advanced STS who received pazopanib.
Article Synopsis
- In patients with inflammatory bowel disease (IBD), interleukin-34 (IL-34) activates harmful signaling pathways, but the triggers for its production are not well-understood.
- The study found that bromodomain-containing 4 (BRD4) is over-expressed in IBD and may enhance IL-34 production, with both proteins showing increased levels and co-localization in inflammatory cells.
- Experiments demonstrated that inhibiting BRD4 led to reduced IL-34 expression, suggesting that BRD4 plays a key role in regulating IL-34 and contributing to inflammation in IBD.
Article Synopsis
- The article with DOI: 10.1016/j.lanepe.2024.100973 is officially retracted.
- The retraction indicates that the content is no longer valid or reliable.
- For readers, this means they should disregard any information or conclusions presented in that article.
Interactions between colorectal cancer (CRC) cells and the noncancerous cells in the tumor microenvironment (TME) induce mechanisms for the escape of tumor cells from immune attack. Hepcidin, a peptide that controls immune cell functions, is overproduced by CRC cells. This study aimed to evaluate whether hepcidin acts as a regulator of anti-tumor immunity in CRC.
View Article and Find Full Text PDF